Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 12/20 | 0.68 |
| ▸ | DRD2 | P14416 | 7/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602187 | 0.89 | HRH4 (0.74) | HRH4HRH3DRD3DRD2HRH1 | |
| SCHEMBL2679610 | 0.88 | HRH4 (1.00) | HRH4HRH3DRD3DRD2POLB | |
| SCHEMBL29699763 | 0.88 | HRH4 (1.00) | HRH4HRH3DRD3DRD2POLB | |
| SCHEMBL605555 | 0.84 | HRH4 (0.77) | HRH4DRD3DRD2HRH1ADRB1 | |
| SCHEMBL605483 | 0.84 | HRH4 (1.00) | HRH4HRH3DRD3DRD2HRH1 | |
| SCHEMBL22615143 | 0.83 | HRH4 (0.89) | HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL603454 | 0.83 | HRH4 (1.00) | HRH4HRH3DRD3DRD2HRH1 | |
| SCHEMBL602069 | 0.83 | HRH4 (0.76) | HRH4DRD3DRD2HRH1ADRB1 | |
| SCHEMBL6383382 | 0.83 | HRH4 (0.72) | HRH4DRD3DRD2HRH1ADRB1 | |
| SCHEMBL28929913 | 0.83 | HRH4 (0.73) | HRH4HRH3DRD3DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803362-B2 | ANTIHISTAMINES SUCH AS (5-CHLORO-1H-INDOL-2-YL)-(4-METHYL-PIPERAZIN-1-YL)-METHANONE, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC OR BRONCHODILATOR AGENTS AND/OR IMMUNOLOGY MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2004-10-12 | — | — | US | disclosed |
| US-20030207893-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207893-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | HRH4 1508/4885HRH3 3119/4885DRD3 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.